DK1625403T3 - Fremgasngsmåde til forudsigelsen, diagnosen og differentialdiagnosen af Alzheimers sygdom - Google Patents

Fremgasngsmåde til forudsigelsen, diagnosen og differentialdiagnosen af Alzheimers sygdom

Info

Publication number
DK1625403T3
DK1625403T3 DK04730881T DK04730881T DK1625403T3 DK 1625403 T3 DK1625403 T3 DK 1625403T3 DK 04730881 T DK04730881 T DK 04730881T DK 04730881 T DK04730881 T DK 04730881T DK 1625403 T3 DK1625403 T3 DK 1625403T3
Authority
DK
Denmark
Prior art keywords
diagnosis
alzheimer
disease
prediction
procedure
Prior art date
Application number
DK04730881T
Other languages
Danish (da)
English (en)
Inventor
Hugo Vanderstichele
Eugeen Vanmechelen
Kaj Blennow
Meyer Geert De
Vesna Kostanjevecki
Original Assignee
Innogenetics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogenetics Nv filed Critical Innogenetics Nv
Application granted granted Critical
Publication of DK1625403T3 publication Critical patent/DK1625403T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
DK04730881T 2003-05-22 2004-05-03 Fremgasngsmåde til forudsigelsen, diagnosen og differentialdiagnosen af Alzheimers sygdom DK1625403T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03447120A EP1480041A1 (en) 2003-05-22 2003-05-22 Method for the prediction, diagnosis and differential diagnosis of Alzheimer's disease
US47762103P 2003-06-11 2003-06-11
PCT/EP2004/050684 WO2004104597A1 (en) 2003-05-22 2004-05-03 Method for the prediction, diagnosis and differential diagnosis of alzheimer's disease

Publications (1)

Publication Number Publication Date
DK1625403T3 true DK1625403T3 (da) 2008-06-09

Family

ID=33041166

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04730881T DK1625403T3 (da) 2003-05-22 2004-05-03 Fremgasngsmåde til forudsigelsen, diagnosen og differentialdiagnosen af Alzheimers sygdom

Country Status (14)

Country Link
US (2) US20040265919A1 (pl)
EP (2) EP1480041A1 (pl)
JP (1) JP4769722B2 (pl)
AT (1) ATE386942T1 (pl)
AU (1) AU2004242203B2 (pl)
CA (1) CA2525781C (pl)
CY (1) CY1110252T1 (pl)
DE (1) DE602004011931T2 (pl)
DK (1) DK1625403T3 (pl)
ES (1) ES2301986T3 (pl)
PL (1) PL1625403T3 (pl)
PT (1) PT1625403E (pl)
SI (1) SI1625403T1 (pl)
WO (1) WO2004104597A1 (pl)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
WO2006014723A2 (en) * 2004-07-19 2006-02-09 Mayo Foundation For Medical Education And Research Predicting alzheimer's disease
US7625560B2 (en) 2004-12-15 2009-12-01 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
EP1838348B1 (en) 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanized amyloid beta antibodies for use in improving cognition
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
HRP20140240T4 (hr) 2005-11-30 2017-02-24 Abbvie Inc. Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba
EP1959996A2 (en) 2005-12-12 2008-08-27 AC Immune S.A. Monoclonal antibody
JP4790013B2 (ja) * 2006-04-13 2011-10-12 エーディア株式会社 β−アミロイドの血中分解速度測定によるアルツハイマー病の検定に用いられる方法及び診断試薬
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
EP2046833B9 (en) 2006-07-14 2014-02-19 AC Immune S.A. Humanized antibody against amyloid beta
WO2008058760A1 (en) * 2006-11-17 2008-05-22 Friedrich-Alexander-Universität Erlangen-Nürnberg Method of differentially diagnosing dementias
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
DK2182983T3 (da) 2007-07-27 2014-07-14 Janssen Alzheimer Immunotherap Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
AU2008311367B2 (en) 2007-10-05 2014-11-13 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
WO2009095454A2 (de) * 2008-02-01 2009-08-06 Brahms Aktiengesellschaft Verfahren zur identifizierung von therapiebedürftigen patienten mit leichten kognitiven störungen und die behandlung derartiger patienten
WO2010009987A2 (en) * 2008-07-21 2010-01-28 Probiodrug Ag Diagnostic antibody assay
EP2344881A4 (en) * 2008-09-26 2012-03-07 Univ Melbourne BIOMARKER FOR MORBUS ALZHEIMER
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
WO2011033046A1 (en) * 2009-09-18 2011-03-24 Probiodrug Ag Novel assay for the detection of amyloid beta peptides
BR112012014060B8 (pt) * 2009-12-11 2021-07-27 Araclon Biotech Sl método para o diagnóstico da doença de alzheimer em um sujeito, para detecção da disfunção cognitiva branda ou para diferenciar a doença de alzheimer da disfunção cognitiva branda
DE102010014684A1 (de) * 2010-04-09 2011-10-13 Universität Duisburg-Essen Neue Ansätze zur Alzheimer-Diagnose
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
EP2598882B1 (en) 2010-07-30 2017-07-26 AC Immune S.A. Safe and functional humanized antibodies for use in treating an amyloidosis
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
EP2511296A1 (en) 2011-04-12 2012-10-17 Araclón Biotech, S. L. Antibody, kit and method for determination of amyloid peptides
JP6231263B2 (ja) * 2012-07-17 2017-11-15 株式会社島津製作所 アフィニティ支持体及びそれを用いた物質の捕捉方法
NZ630542A (en) 2012-08-16 2017-06-30 Ipierian Inc Methods of treating a tauopathy
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
US10304006B2 (en) * 2013-02-15 2019-05-28 The Charles Stark Draper Laboratory, Inc. Method for integrating and fusing heterogeneous data types to perform predictive analysis
JP2017512751A (ja) 2014-02-14 2017-05-25 アイピエリアン，インコーポレイティド タウペプチド、抗タウ抗体、およびそれらの使用方法
US20180252665A1 (en) * 2014-05-27 2018-09-06 Case Western Reserve University System and methods for the detection of biomarkers of neurodegenerative disorders
EP3149486A1 (en) * 2014-05-30 2017-04-05 Biocross, S.L. Method for the diagnosis of alzheimer's disease and mild cognitive impairment
EP2950102A1 (en) * 2014-05-30 2015-12-02 Biocross, S.L. Method for the diagnosis of alzheimer s disease and mild cognitive impairment
CN113884683A (zh) * 2020-07-30 2022-01-04 山东京济生物工程有限公司 一种快速检测Aβ42的双抗体夹心ELISA试剂盒
US20220260559A1 (en) * 2020-11-04 2022-08-18 Seer, Inc. Biomarkers for diagnosing alzheimer's disease
JP2024514049A (ja) * 2021-03-16 2024-03-28 ニューロビジョン イメージング， インコーポレイテッド アルツハイマー病関連状態を診断するための生物流体ベースの方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262332A (en) * 1989-04-05 1993-11-16 Brigham And Women's Hospital Diagnostic method for Alzheimer's disease: examination of non-neural tissue
US5766846A (en) * 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
ATE239797T1 (de) * 1993-01-25 2003-05-15 Takeda Chemical Industries Ltd Antikörper gegen beta-amyloid oder derivative davon und seine verwendung
CA2306501C (en) * 1997-10-14 2011-03-29 Luminex Corporation Precision fluorescently dyed particles and methods of making and using same
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US20020182660A1 (en) * 2000-02-18 2002-12-05 Fong Kei-Lai L. N- and C-terminus specific immunoassays for full length beta-amyloid peptide-Abeta(1-40), Abeta(1-39), Abeta(1-40), Abeta(1-42) , and Abeta(1-43)
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
ATE277952T1 (de) * 2001-06-12 2004-10-15 Wiltfang Jens Monoklonaler antikörper, mbab 1e8, welcher für die zwei ersten n-terminalen aminosäuren von amyloid-beta-peptiden spezifisch ist und dessen verwendung zum nachweis von amyloid-beta peptiden und/oder sappa
PT1416965E (pt) * 2001-08-17 2008-04-01 Lilly Co Eli Método de ensaio para a doença de alzheimer

Also Published As

Publication number Publication date
EP1625403A1 (en) 2006-02-15
PT1625403E (pt) 2008-05-28
PL1625403T3 (pl) 2008-10-31
AU2004242203B2 (en) 2008-12-11
AU2004242203A1 (en) 2004-12-02
ES2301986T3 (es) 2008-07-01
CA2525781A1 (en) 2004-12-02
CY1110252T1 (el) 2015-01-14
CA2525781C (en) 2013-08-13
SI1625403T1 (sl) 2008-08-31
JP2007522434A (ja) 2007-08-09
DE602004011931D1 (de) 2008-04-03
US20040265919A1 (en) 2004-12-30
JP4769722B2 (ja) 2011-09-07
WO2004104597A1 (en) 2004-12-02
EP1480041A1 (en) 2004-11-24
US20080057593A1 (en) 2008-03-06
EP1625403B1 (en) 2008-02-20
ATE386942T1 (de) 2008-03-15
DE602004011931T2 (de) 2009-09-10

Similar Documents

Publication Publication Date Title
DK1625403T3 (da) Fremgasngsmåde til forudsigelsen, diagnosen og differentialdiagnosen af Alzheimers sygdom
DK2211183T3 (da) Fremgangsmåde til diagnosticering og overvågning af Alzheimer's sygdom
DE60229051D1 (de) Humanisierte antikörper
DK1155325T3 (da) Fremgangsmåde til diagnosticering af og skelnen mellem typer af slagtilfælde
ATE539069T1 (de) Isotopenmarkierte benzofuranverbindungen als bilddarstellende mittel für amyloidogene proteine
WO2007067926A3 (en) Analyzing administrative healthcare claims data and other data sources
CY1108182T1 (el) Μεσα εντοπισμου του παθολογικου μετασχηματισμου της πρωτεϊνης app και εφαρμογες τους
DK1187591T3 (da) IBD-associerede mikrobielle antigener og fremgangsmåder til at anvende samme
NO20034020L (no) Nye MHC molekylforbindelser, og metoder for anvendelse av disse forbindelsene for diagnose og terapi, og anvendelse av MHC molekyler
DK2146209T3 (da) Neurodegenerative markører for Alzheimer's sygdom
DK1348029T3 (da) Materialer og fremgangsmåder involveret i proteinaggregering i neurodegenerative sygdomme
DK2380583T3 (da) Små peptider til behandling af Alzheimers sygdom og andre beta-amyloidprotein-fibrillogeneseforstyrrelser
ATE551357T1 (de) Markerpeptid für die alzheimer-krankheit
EP1664718A4 (en) DIAGNOSIS AND MONITORING OF HEPATOCELLULAR CARCINOMA
EP1776470A4 (en) REAGENTS, KITS AND PROCEDURES FOR IMMUNE PROTECTION OF EPITOPES ON MOLECULES
ATE306659T1 (de) Küvette für ein lesegerät zur bestimmung von substanzen mittels der evaneszenzfeldmethode
WO2001020533A3 (en) Creation of a database of biochemical data and methods of use
ATE490339T1 (de) Diagnostikum für osteoporose
WO2004041077A3 (en) Method for assessing navigational capacity
ATE347698T1 (de) Verfahren zum nachweis von alzheimer-krankheit
FR2849205B1 (fr) Procede d'amplification de la detection de la prpsc et utilisation d'un ligand adjuvant macrocyclique pour une telle amplification
WO2004001422A3 (en) Diagnostic and therapeutic use of ras-gtpase-activating sh3-domain-binding protein 2 (g3bp2) for neurodegenerative diseases
ATE459877T1 (de) Diagnostikum für die frühe phase von morbus alzheimer
DK1379882T3 (da) Diagnostisk og terapeutisk anvendelse af et nuclearbegrænset protein til Alzheimers syge og beslægtede neurodegenerative forstyrrelser
SI1639139T1 (sl) Postopki za detekcijo Alzheimerjeve bolezni